Sichuan Kelun Pharmaceutical Co., Ltd. Class A
002422.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$63.19B
Close$
$19.41
55.1% downside
Current Fair Value
55.1% downsideOvervalued by 55.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $63.19 Billion |
|---|---|
| Enterprise Value | $62.88 Billion |
| Dividend Yield | $0.59 (1.50%) |
| Earnings per Share | $1.07 |
| Beta | -0.17 |
| Outstanding Shares | 1,590,431,208 |
Return
| Return on Equity | 7.43% |
|---|---|
| Return on Assets | 4.40% |
| Return on Invested Capital | 6.00% |
Valuation & Multiples
| P/E Ratio | 34.24 |
|---|---|
| PEG | 55.33 |
| Price to Sales | 3.93 |
| Price to Book Ratio | 2.4 |
| Enterprise Value to Revenue | 3.44 |
| Enterprise Value to EBIT | 33.59 |
| Enterprise Value to Net Income | 34 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.24 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 26, 2026
EPS Estimate
$0.32
Average shareholder expectationRevenue Estimate
$5.57 B
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$0.21
Average shareholder expectationRevenue Estimate
$4.49 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Sichuan Kelun Pharmaceutical Co., Ltd. Class A
20,127 employees
CEO: Si Chuan Liu Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. ...